Overview

Adding Mitomycin C to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

Open label, randomised phase 3 trial of the addition of Mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer. The study aim is to compare disease-free survival between treatment arms: BCG alone versus Mitomyicn C in addition to BCG.

Phase:

Phase 3

Details

Lead Sponsor:

University of Sydney

Collaborators:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Cancer Australia

Treatments:

BCG Vaccine
Mitomycin
Mitomycins